Seventh Sense: Tapping Into Blood Collection Market

The video discusses the fear of needles and its impact on diagnostic tests, introducing the Tap 100 device as a solution. The Tap 100 uses micro-needles for a painless blood draw, unlike Theranos, which focuses on analytics. The CEO highlights training and challenges faced, including issues with blood sample size. The FDA approval process is outlined, and the integration of tech and healthcare is discussed, noting regulatory challenges.

What is the main problem that the new blood testing device aims to address?

How does the tap 100 device collect blood compared to traditional methods?

What are the differences between the new company and Theranos in terms of their approach to blood testing?

What challenges did the CEO mention regarding the human error in collecting blood samples?

What regulatory challenges do companies face when trying to innovate in the healthcare sector?